title: [Place of ipriflavone in the therapy of osteoporosis].
abstract: In Hungary ipriflavone has been marketed under the name Osteochin. After a short summary of the clinically proven results the article tries to position ipriflavone among antiosteoporotic drugs. Not only on the basis of preclinical results the article shows that Osteochin--as a non hormonal agent--can be given to those patients who can not receive hormone replacement therapy, there are grounds for giving combination of ipriflavone and a low dose estrogen. Ipriflavone's advantages are that it decreases acute and chronic back pain due to osteoporosis, it is rapidly metabolized and is quickly eliminated therefore it can not cause any long acting side effects, patients' compliance is good. Ipriflavone, the original Hungarian compound is an alternative possibility in the treatment of osteoporosis.
authors: Chinoin Gyógyszer-és Vegyészeti Termékek Gyára Rt, Budapest.
authors: B
authors: B
authors: Zsuzsanna
mesh_terms: D018849:Controlled Clinical Trials as Topic; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000009:adverse effects / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D010146:Pain / Q000517:prevention & control; D010349:Patient Compliance
chemical_list: D007529:Isoflavones; C018986:ipriflavone
vernacular_title: Az ipriflavon helye az osteoporosis terápiájában.